Baxter International Inc. (BAX) on Wednesday said China's State Food and Drug Administration or SFDA has approved ADVATE (Recombinant Human Coagulation Factor VIII for injection) for the control and prophylaxis of bleeding in individuals with hemophilia A.
Over 50,000 people in China are estimated to be living with hemophilia A. ADVATE is infused directly into the bloodstream. It works by temporarily raising the level of factor VIII in the bloodstream, allowing the body's blood clotting process to properly function. ADVATE is now approved in 54 countries worldwide.
''The approval of ADVATE in China marks an important milestone for Baxter and supports our ongoing commitment to treating individuals living with hemophilia,'' said Ludwig Hantson, Ph.D., president of Baxter's BioScience business.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.